Key result
A 48-hour NT-proBNP level >4988 pg/ml strongly predicted adverse cardiovascular outcomes in patients with acute heart failure, with a relative risk of 8.1.
Why the study?
Does a multimarker strategy of biomarkers predict adverse outcomes in patients with acute heart failure?
Observational (n=52)
No
Does a multimarker strategy of biomarkers predict adverse outcomes in patients with acute heart failure?
Effect estimate: RR 8.1 (95% CI 2.05-31.92)
p-value: p=0.0028
In patients with acute heart failure, baseline and serial measurements of NT-proBNP are predictive of adverse cardiovascular outcomes, whereas hsTropT, hsCRP, and uric acid are not, despite being frequently elevated.
May aid acute HF risk stratification via serial NT-proBNP; leaves open whether multimarker panels add value.
BACKGROUND: Heart failure (HF) is a growing public health problem. Patients often present to emergency department (ED) with acute onset dyspnea where a rapid triage is required to avoid misdiagnosis and to institute appropriate therapy. An objective risk-stratification in the ED is warranted to identify patients at high risk of adverse outcomes, so that more intensive therapy and vigilant follow-up after discharge are instituted. METHODS AND RESULTS: Fifty two consecutive acute HF (AHF) patients in NYHA class III/IV were enrolled for the present study. N-terminal pro B-type natriuretic peptide (NT-proBNP), high-sensitivity cardiac troponin T (hsTropT), high-sensitivity C-reactive protein (hsCRP) and Uric acid (UA) were evaluated at admission; a second sample for NT-proBNP and hsTropT was obtained 48h later. The end-point of the study, a composite of cardiovascular death, rehospitalisation for worsening HF symptoms and refractory HF was reached in 32.7% of patients during a median follow-up of 4.8mnth. Although, hsTropT (>0.014ng/ml), hsCRP (>0.5mg/dl) and UA (>5.6mg/dl for females and >7 mg/dl for males) were elevated in the vast majority of patients (92.3%, 75% and 63.5% respectively), baseline and changing patterns of NT-proBNP following treatment were the only predictors of adverse outcomes on follow-up. A significant correlation between hsTropT, hsCRP and UA was observed suggesting a link between inflammation, myocyte injury and oxidative stress in AHF. CONCLUSION: Baseline and changing patterns of NT-proBNP predicted adverse outcomes on follow-up suggesting that a strategy of serial measurement of NT-proBNP could prove invaluable in early risk stratification. Further research is needed to understand the link between inflammation, myocyte injury and oxidative stress in AHF which could provide potential therapeutic targets.
No takes yet. Share an insight, caveat, or question.
Pothur R. Srinivas (2014) conducted an observational in Acute heart failure (n=52). 48-hour NT-proBNP >4988 pg/ml vs. 48-hour NT-proBNP ≤4988 pg/ml was evaluated on Composite of cardiovascular death, rehospitalisation for worsening HF symptoms and refractory HF (RR 8.1, 95% CI 2.05-31.92, p=0.0028). A 48-hour NT-proBNP level >4988 pg/ml strongly predicted adverse cardiovascular outcomes in patients with acute heart failure, with a relative risk of 8.1.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: